Miniatura

Fitxers

GuerraMendozaY_Hum_Vaccin_Immunother_2019.pdf (2.84 MB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2019-04-23

Llicència de publicació

cc by (c) GlaxoSmithKline Biologicals S. A., 2019
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/135358

Safety profile of the RTS,S/AS01 malaria vaccine in infants and children: additional data from a phase III randomized controlled trial in sub-Saharan Africa

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

http://dx.doi.org/10.1080/21645515.2019.1586040

Resum

A phase III, double-blind, randomized, controlled trial (NCT00866619) in sub-Saharan Africa showed RTS,S/AS01 vaccine efficacy against malaria. We now present in-depth safety results from this study. 8922 children (enrolled at 5-17\xC2\xA0months) and 6537 infants (enrolled at 6-12\xC2\xA0weeks) were 1:1:1-randomized to receive 4 doses of RTS,S/AS01 (R3R) or non-malaria control vaccine (C3C), or 3 RTS,S/AS01 doses plus control (R3C). Aggregate safety data were reviewed by a multi-functional team. Severe malaria with Blantyre Coma Score \xE2\x89\xA42 (cerebral malaria [CM]) and gender-specific mortality were assessed post-hoc. Serious adverse event (SAE) and fatal SAE incidences throughout the study were 24.2%-28.4% and 1.5%-2.5%, respectively across groups; 0.0%-0.3% of participants reported vaccination-related SAEs. The incidence of febrile convulsions in children was higher during the first 2-3 days post-vaccination with RTS,S/AS01 than with control vaccine, consistent with the time window of post-vaccination febrile reactions in this study (mostly the day after vaccination). A statistically significant numerical imbalance was observed for meningitis cases in children (R3R: 11, R3C: 10, C3C: 1) but not in infants. CM cases were more frequent in RTS,S/AS01-vaccinated children (R3R: 19, R3C: 24, C3C: 10) but not in infants. All-cause mortality was higher in RTS,S/AS01-vaccinated versus control girls (2.4% vs 1.3%, all ages) in our setting with low overall mortality. The observed meningitis and CM signals are considered likely chance findings, that - given their severity - warrant further evaluation in phase IV studies and WHO-led pilot implementation programs to establish the RTS,S/AS01 benefit-risk profile in real-life settings.

Matèries

Vacuna de la malària, Infants, Àfrica subsahariana

Matèries (anglès)

Malaria vaccine, Children, Sub-Saharan Africa

Citació

Col·leccions

Articles publicats en revistes (ISGlobal)

Citació

GUERRA MENDOZA, Yolanda, GARRIC, Elodie, LEACH, Amanda, LIEVENS, Marc, OFORI-ANYINAM, Opokua, PIRÇON, Jean-yves, STEGMANN, Jens-ulrich, VANDOOLAEGHE, Pascale, OTIENO, Lucas, OTIENO, Walter, OWUSU-AGYEI, Seth, SACARLAL, Jahit, MASOUD, Nahya salim, SORGHO, Hermann, TANNER, Marcel, TINTO, Halidou, VALEA, Innocent, MTORO, Ali takadir, NJUGUNA, Patricia, ONEKO, Martina, OTIENO, Godfrey allan, OTIENO, Kephas, GESASE, Samwel, HAMEL, Mary j., HOFFMAN, Irving, KAALI, Seyram, KAMTHUNZI, Portia, KREMSNER, Peter g., LANASPA, Miguel, LELL, Bertrand, LUSINGU, John, MALABEJA, Anangisye, AIDE, Pedro carlos paulino, AKOO, Pauline, ANSONG, Daniel, ASANTE, Kwaku poku, BERKLEY, James a., ADJEI, Samuel, AGBENYEGA, Tsiri, AGNANDJI, Selidji todagbe, SCHUERMAN, Lode. Safety profile of the RTS,S/AS01 malaria vaccine in infants and
                children: additional data from a phase III randomized controlled
                trial in sub-Saharan Africa. _Human Vaccines & Immunotherapeutics_. 2019. [consulta: 23 de gener de 2026]. ISSN: 2164-5515. [Disponible a: https://hdl.handle.net/2445/135358]

Exportar metadades

JSON - METS

Compartir registre